• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Chimeric virus-like Particles Made Using GAG and M1 Capsid Proteins Providing Dual Drug Delivery and Vaccination Platform

tetano

Editor, Senior Moderator
Mol Pharm. 2015 Jan 27. [Epub ahead of print]
[h=1]Chimeric virus-like Particles Made Using GAG and M1 Capsid Proteins Providing Dual Drug Delivery and Vaccination Platform.[/h] Deo VK, Kato T, Park EY.
[h=3]Abstract[/h] Nanobiomaterials such as enveloped virus-like particles with specificity can serve a dual function of vaccination and drug delivery system. Here, we expressed colon carcinoma cell-targeting chimeric virus-like particles (VLPs) made using two capsid proteins, gag and M1 from influenza virus A/swine flu/Iowa/15/30/H1N1 in silkworms. These chimeric VLPs displayed a glycosylphosphatidylinositol-anchored single-chain variable fragment region targeting colon carcinoma cells, and their shape was smooth with an average particle size of 21 nm in diameter. Large unilamellar vesicles made from DOPC:DOPA (2:1) containing calcein-AM (10 μM) or doxorubicin (13.7 nM) were used to package chimeric VLPs. VLPs showed high specificity in targeting cancer cells and delivered the dye and drug to cells successfully. Chimeric VLPs were injected into BALB/c mice and the serum raised showed specificity for M1 protein as a model.


PMID: 25627427 [PubMed - as supplied by publisher]
 
Back
Top Bottom